FDA Approves Supplemental Application for OGSIVEO (Nirogacestat Hydro bromide)
The FDA has approved a supplemental application for OGSIVEO, containing Nirogacestat Hydrobromide.
Asset / Drug
Drug and asset intelligence for SPRINGWORKS with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.